659 related articles for article (PubMed ID: 15208518)
21. Equivalent occupancy of dopamine D1 and D2 receptors with clozapine: differentiation from other atypical antipsychotics.
Tauscher J; Hussain T; Agid O; Verhoeff NP; Wilson AA; Houle S; Remington G; Zipursky RB; Kapur S
Am J Psychiatry; 2004 Sep; 161(9):1620-5. PubMed ID: 15337652
[TBL] [Abstract][Full Text] [Related]
22. Clozapine use in patients with schizophrenia and the risk of diabetes, hyperlipidemia, and hypertension: a claims-based approach.
Lund BC; Perry PJ; Brooks JM; Arndt S
Arch Gen Psychiatry; 2001 Dec; 58(12):1172-6. PubMed ID: 11735847
[TBL] [Abstract][Full Text] [Related]
23. Risk of discontinuation of atypical antipsychotic agents in the treatment of schizophrenia.
Mullins CD; Obeidat NA; Cuffel BJ; Naradzay J; Loebel AD
Schizophr Res; 2008 Jan; 98(1-3):8-15. PubMed ID: 17596914
[TBL] [Abstract][Full Text] [Related]
24. Can atypical antipsychotics improve tardive dyskinesia associated with other atypical antipsychotics? Case report and brief review of the literature.
Peritogiannis V; Tsouli S
J Psychopharmacol; 2010 Jul; 24(7):1121-5. PubMed ID: 19395427
[TBL] [Abstract][Full Text] [Related]
25. Risk of falls and fractures in older adults using atypical antipsychotic agents: a propensity score-adjusted, retrospective cohort study.
Chatterjee S; Chen H; Johnson ML; Aparasu RR
Am J Geriatr Pharmacother; 2012 Apr; 10(2):83-94. PubMed ID: 22306198
[TBL] [Abstract][Full Text] [Related]
26. Do certain atypical antipsychotics increase the risk of diabetes? A critical review of 17 pharmacoepidemiologic studies.
Ramaswamy K; Masand PS; Nasrallah HA
Ann Clin Psychiatry; 2006; 18(3):183-94. PubMed ID: 16923657
[TBL] [Abstract][Full Text] [Related]
27. Atypical antipsychotic therapy for treatment of schizophrenia in Hong Kong Chinese patients--a cost analysis.
Law WL; Hui HY; Young WM; You JH
Int J Clin Pharmacol Ther; 2007 May; 45(5):264-70. PubMed ID: 17542348
[TBL] [Abstract][Full Text] [Related]
28. [Effect of side-effects and complications caused by atypical neuroleptics on the effectiveness of therapy in patients with schizophrenia].
Danilov DS
Zh Nevrol Psikhiatr Im S S Korsakova; 2010; 110(3):48-55. PubMed ID: 20517226
[TBL] [Abstract][Full Text] [Related]
29. Risk of arrest in persons with schizophrenia and bipolar disorder in a Florida Medicaid program: the role of atypical antipsychotics, conventional neuroleptics, and routine outpatient behavioral health services.
Van Dorn RA; Andel R; Boaz TL; Desmarais SL; Chandler K; Becker MA; Howe A
J Clin Psychiatry; 2011 Apr; 72(4):502-8. PubMed ID: 21527125
[TBL] [Abstract][Full Text] [Related]
30. Atypical antipsychotics and diabetes mellitus.
Schwenkreis P; Assion HJ
World J Biol Psychiatry; 2004 Apr; 5(2):73-82. PubMed ID: 15179666
[TBL] [Abstract][Full Text] [Related]
31. Time to discontinuation of atypical versus typical antipsychotics in the naturalistic treatment of schizophrenia.
Ascher-Svanum H; Zhu B; Faries D; Landbloom R; Swartz M; Swanson J
BMC Psychiatry; 2006 Feb; 6():8. PubMed ID: 16504026
[TBL] [Abstract][Full Text] [Related]
32. Differential rates of treatment discontinuation in clinical trials as a measure of treatment effectiveness for olanzapine and comparator atypical antipsychotics for schizophrenia.
Kinon BJ; Liu-Seifert H; Adams DH; Citrome L
J Clin Psychopharmacol; 2006 Dec; 26(6):632-7. PubMed ID: 17110821
[TBL] [Abstract][Full Text] [Related]
33. Impact of patient selection criteria and treatment history on comparisons of alternative therapies: a case study of atypical antipsychotics.
Marshall TS; McCombs JS; Stafkey-Mailey D
Value Health; 2009 Jun; 12(4):473-80. PubMed ID: 18798808
[TBL] [Abstract][Full Text] [Related]
34. [A naturalistic, observational study of outpatients with schizophrenia: efficacy and safety results after 6 months. The International Schizophrenia Outpatient Health Outcomes study, IC-SOHO].
István S; Agoston T; Tamás T; Zoltán J
Neuropsychopharmacol Hung; 2007 Oct; 9(3):115-24. PubMed ID: 18399029
[TBL] [Abstract][Full Text] [Related]
35. The value of atypical antipsychotics in the treatment of schizophrenia.
Jessen LM
Manag Care; 2002 Jul; 11(7 Suppl):8-12; discussion 12-3. PubMed ID: 12181875
[No Abstract] [Full Text] [Related]
36. Comparison of incidence rates of cerebrovascular accidents and transient ischaemic attacks in observational cohort studies of patients prescribed risperidone, quetiapine or olanzapine in general practice in England including patients with dementia.
Layton D; Harris S; Wilton LV; Shakir SA
J Psychopharmacol; 2005 Sep; 19(5):473-82. PubMed ID: 16166184
[TBL] [Abstract][Full Text] [Related]
37. Pharmacy cost evaluation of risperidone, olanzapine, and quetiapine for the treatment of schizophrenia in acute care inpatient settings.
Mladsi DM; Grogg AL; Irish WD; Lopez RB; Degen K; Swann A; Nimsch CT
Curr Med Res Opin; 2004 Dec; 20(12):1883-93. PubMed ID: 15701206
[TBL] [Abstract][Full Text] [Related]
38. Antipsychotic treatment discontinuation in previously untreated patients with schizophrenia: 36-month results from the SOHO study.
Haro JM; Novick D; Suarez D; Roca M
J Psychiatr Res; 2009 Jan; 43(3):265-73. PubMed ID: 18644606
[TBL] [Abstract][Full Text] [Related]
39. Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis.
Henderson DC; Cagliero E; Copeland PM; Borba CP; Evins AE; Hayden D; Weber MT; Anderson EJ; Allison DB; Daley TB; Schoenfeld D; Goff DC
Arch Gen Psychiatry; 2005 Jan; 62(1):19-28. PubMed ID: 15630069
[TBL] [Abstract][Full Text] [Related]
40. Comparing adherence to and persistence with antipsychotic therapy among patients with bipolar disorder.
Hassan M; Madhavan SS; Kalsekar ID; Makela EH; Rajagopalan K; Islam S; Kavookjian J; Miller LA
Ann Pharmacother; 2007 Nov; 41(11):1812-8. PubMed ID: 17925501
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
